Information Provided By: 
Fly News Breaks for March 28, 2016
ENDP
Mar 28, 2016 | 06:50 EDT
Amneal Pharmaceuticals became the first company to launch a generic version of Endo International's Voltaren Gel, Piper Jaffray analyst David Amsellem tells investors in a research note. More generic entrants will likely be seen, but an authorized generic distributed by Endo should limit the impact, the analyst contends. Amsellem believes the stock is reflecting a business model that is not sustainable. He disagrees with this view. The analyst lowered his price target for Endo shares to $79 from $81 and reiterates an Overweight rating on the name.
News For ENDP From the Last 2 Days
There are no results for your query ENDP
